IMPL insider filings
IMPEL PHARMACEUTICALS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-19. Screen IMPL transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for IMPL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — IMPEL PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-12-19 | 4 | Vivo Capital VIII, LLC — 10% owner Vivo Capital Fund VIII, L.P. — 10% owner Vivo Capital Surplus Fund VIII, L.P. — 10% owner | Sale (S): 87,934 @ $0.29 · Sale (S): 12,066 @ $0.29 · Sale (S): 209,029 @ $0.11 · Sale (S): 28,682 @ $0.11 · Sale (S): 208,657 @ $0.08 · Sale (S): 28,632 @ $0.08 | EDGAR |
| 2023-12-04 | 4 | Oaktree-TCDRS Strategic Credit, LLC — 10% owner Oaktree-Forrest Multi-Strategy,LLC — 10% owner Oaktree-TBMR Strategic Credit Fund C, LLC — 10% owner Oaktree-TBMR Strategic Credit Fund F, LLC — 10% owner Oaktree-TBMR Strategic Credit Fund G, LLC — 10% owner Oaktree-TSE 16 Strategic Credit, LLC — 10% owner INPRS Strategic Credit Holdings, LLC — 10% owner Oaktree Gilead Investment Fund AIF (Delaware), L.P. — 10% owner Oaktree Specialty Lending Corp — 10% owner Oaktree Strategic Credit Fund — 10% owner | Other (J): 445,294 (derivative) | EDGAR |
| 2023-12-04 | 4 | Oaktree GCP Fund Delaware Holdings, L.P. — 10% owner Oaktree Diversified Income Fund Inc. — 10% owner Oaktree AZ Strategic Lending Fund, L.P. — 10% owner Oaktree Loan Acquisition Fund, L.P. — 10% owner Oaktree LSL Fund Holdings EURRC S.a.r.l. — 10% owner Oaktree LSL Fund Delaware Holdings EURRC, L.P. — 10% owner Oaktree PRE Life Sciences Fund, L.P. — 10% owner Oaktree Capital Group, LLC — 10% owner Atlas OCM Holdings, LLC — 10% owner | Other (J): 445,294 (derivative) | EDGAR |
| 2023-12-04 | 4 | BROOKFIELD Corp /ON/ — 10% owner BAM Partners Trust — 10% owner Brookfield Asset Management ULC — 10% owner | Other (J): 445,294 (derivative) | EDGAR |
| 2023-06-20 | 4 | Cline Darren S — Director | Grant/award (A): 13,222 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Allison David D. — Director | Grant/award (A): 13,222 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Wilfong Diane E. — Director | Grant/award (A): 13,222 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | SHAH MAHENDRA — Director | Grant/award (A): 13,222 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | NELSON TIMOTHY S — Director | Grant/award (A): 13,222 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | Kalb Michael Wayne — CFO | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
| 2023-04-14 | 4 | Cline Darren S — Director | Grant/award (A): 20,013 (derivative) @ $0 | EDGAR |
| 2023-02-16 | 4 | Paolillo Leonard — Chief Commercial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-02-16 | 4 | Hoekman John — Chief Scientific Officer | Grant/award (A): 42,500 (derivative) @ $0 | EDGAR |
| 2023-02-16 | 4 | Leaman John Harold — Chief Fin. & Business Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2023-02-16 | 4 | ADAMS ADRIAN — COB, CEO and President, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | Leaman John Harold — Chief Fin. & Business Officer | Option exercise (M): 10,571 @ $0 · Tax withholding (F): 3,627 @ $3.75 · Option exercise (M): 10,571 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Allison David D. — Director | Grant/award (A): 12,789 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Wilfong Diane E. — Director | Grant/award (A): 12,789 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | SHAH MAHENDRA — Director | Grant/award (A): 12,789 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | NELSON TIMOTHY S — Director | Grant/award (A): 12,789 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | PARKER H STEWART — Director | Grant/award (A): 12,789 (derivative) @ $0 | EDGAR |
| 2022-03-30 | 4 | SHREWSBURY STEPHEN B — Chief Medical Officer | Option exercise (M): 24,606 @ $1.97 · Option exercise (M): 24,606 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Paolillo Leonard — Chief Commercial Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Leaman John Harold — Chief Fin. & Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Hoekman John — Chief Scientific Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | SHREWSBURY STEPHEN B — Chief Medical Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | ADAMS ADRIAN — COB, CEO and President, Director | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | Hoekman John — Chief Scientific Officer | Option exercise (M): 20,000 @ $1.64 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2021-11-22 | 4 | NELSON TIMOTHY S — Director | Purchase (P): 10,000 @ $10.76 | EDGAR |
| 2021-10-21 | 4 | Leaman John Harold — Chief Fin. & Business Officer | Grant/award (A): 10,571 (derivative) @ $0 | EDGAR |
| 2021-09-22 | 4 | SHREWSBURY STEPHEN B — Chief Medical Officer | Option exercise (M): 14,780 @ $1.97 · Option exercise (M): 4,650 @ $2.46 · Option exercise (M): 53,954 @ $2.95 · Option exercise (M): 14,780 (derivative) @ $0 · Option exercise (M): 4,650 (derivative) @ $0 · Option exercise (M): 53,954 (derivative) @ $0 | EDGAR |
| 2021-08-19 | 4 | ADAMS ADRIAN — COB, CEO and President, Director | Purchase (P): 17,203 @ $13.81 · Purchase (P): 2,197 @ $14.91 · Purchase (P): 600 @ $15.89 | EDGAR |
| 2021-07-26 | 4 | Paolillo Leonard — Chief Commercial Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-07-26 | 4 | Leaman John Harold — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-07-26 | 4 | Hoekman John — Chief Scientific Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-07-26 | 4 | SHREWSBURY STEPHEN B — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-07-26 | 4 | ADAMS ADRIAN — COB, CEO and President, Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-07-13 | 4 | Allison David D. — Director | Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2021-07-13 | 4 | Wilfong Diane E. — Director | Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2021-07-13 | 4 | SHAH MAHENDRA — Director | Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2021-07-13 | 4 | NELSON TIMOTHY S — Director | Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2021-07-13 | 4 | PARKER H STEWART — Director | Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2021-06-22 | 4/A | PARKER H STEWART — Director | Holdings only — no transactions reported | EDGAR |
| 2021-06-07 | 4/A | Hoekman John — Chief Scientific Officer | Conversion (C): 4,253 @ $0 · Conversion (C): 69,657 (derivative) @ $0 | EDGAR |
| 2021-04-29 | 4 | Hoekman John — Chief Scientific Officer | Conversion (C): 4,523 · Other (J): 275 @ $0 · Option exercise/expiry (X): 8,523 (derivative) @ $8.19 · Option exercise/expiry (X): 8,523 (derivative) @ $0 · Conversion (C): 69,657 (derivative) @ $0 | EDGAR |
| 2021-04-29 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Conversion (C): 2,309,791 · Purchase (P): 450,000 @ $15 · Conversion (C): 5,876,034 (derivative) @ $0 · Conversion (C): 8,201,930 (derivative) @ $0 · Conversion (C): 8,845,942 (derivative) @ $0 · Conversion (C): 13,233,885 (derivative) @ $0 · +1 more | EDGAR |
| 2021-04-29 | 4 | 5AM Ventures V, L.P. — 10% owner 5AM Partners V, LLC — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner Schwab Andrew J. — 10% owner 5AM Opportunities I, L.P. — 10% owner 5AM Opportunities I (GP), LLC — 10% owner | Conversion (C): 808,259 · Conversion (C): 540,265 · Conversion (C): 500,932 · Conversion (C): 358,878 · Conversion (C): 101,457 @ $13.50 · Purchase (P): 575,000 @ $15 · +5 more | EDGAR |
| 2021-04-29 | 4 | PARKER H STEWART — Director | Conversion (C): 3,732 · Conversion (C): 7,355 · Other (J): 458 @ $0 · Conversion (C): 8,793 · Other (J): 1,666 @ $0 · Conversion (C): 271 @ $13.50 · +8 more | EDGAR |
| 2021-04-29 | 4 | Norwest Venture Partners XIV, LP — 10% owner Crowe Jeffrey — 10% owner HAQUE PROMOD — 10% owner Kossow Jon Erik — 10% owner | Conversion (C): 98,927 @ $13.50 · Conversion (C): 2,153,271 @ $0 · Purchase (P): 825,000 @ $15 · Conversion (C) @ $0 · Conversion (C): 35,256,206 (derivative) @ $0 | EDGAR |
| 2021-04-29 | 4 | KKR Iris Investors LLC — 10% owner KKR Healthcare Strategic Growth Fund L.P. — 10% owner KKR Associates HCSG L.P. — 10% owner KKR HCSG GP LLC — 10% owner KKR Group Partnership L.P. — 10% owner KKR Group Holdings Corp. — 10% owner KKR & Co. Inc. — 10% owner KKR Management LLP — 10% owner KRAVIS HENRY R — 10% owner ROBERTS GEORGE R — 10% owner | Conversion (C): 2,583,926 · Other (J): 118,712 @ $13.50 · Purchase (P): 1,100,000 @ $15 · Conversion (C): 42,307,448 (derivative) | EDGAR |
Recent 8-K events — IMPEL PHARMACEUTICALS INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-03-12 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-01-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-12-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-11-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-10-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-10-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMPL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs